See more : QuinStreet, Inc. (QNST) Income Statement Analysis – Financial Results
Complete financial analysis of NGM Biopharmaceuticals, Inc. (NGM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NGM Biopharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Zhang Jia Jie Tourism Group Co., Ltd (000430.SZ) Income Statement Analysis – Financial Results
- DaikyoNishikawa Corporation (4246.T) Income Statement Analysis – Financial Results
- Suzuken Co., Ltd. (SZUKF) Income Statement Analysis – Financial Results
- Tonopah Divide Mining Co. (TODM) Income Statement Analysis – Financial Results
- Nutroganics, Inc. (NUTTQ) Income Statement Analysis – Financial Results
NGM Biopharmaceuticals, Inc. (NGM)
About NGM Biopharmaceuticals, Inc.
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an antagonist antibody that binds GFRAL that is in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy; NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced solid tumors; and NGM831 and NGM438 for the treatment of advanced solid tumors. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck & Co., Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4.42M | 55.33M | 77.88M | 87.37M | 103.54M | 108.67M | 77.14M | 85.59M |
| Cost of Revenue | 2.22M | 5.98M | 7.90M | 163.97M | 129.25M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.20M | 49.35M | 69.98M | -76.60M | -25.71M | 108.67M | 77.14M | 85.59M |
| Gross Profit Ratio | 49.72% | 89.19% | 89.86% | -87.68% | -24.83% | 100.00% | 100.00% | 100.00% |
| Research & Development | 112.01M | 181.07M | 161.71M | 163.97M | 129.25M | 95.71M | 79.74M | 82.11M |
| General & Administrative | 37.84M | 40.52M | 36.87M | 27.23M | 23.63M | 17.27M | 14.83M | 11.85M |
| Selling & Marketing | -1.11M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 36.74M | 40.52M | 36.87M | 27.23M | 23.63M | 17.27M | 14.83M | 11.85M |
| Other Expenses | -234.00K | -132.00K | -60.00K | -593.00K | -147.00K | 199.00K | -152.00K | 133.00K |
| Operating Expenses | 148.74M | 221.58M | 198.58M | 191.20M | 152.88M | 112.98M | 94.57M | 93.95M |
| Cost & Expenses | 150.96M | 221.58M | 198.58M | 191.20M | 152.88M | 112.98M | 94.57M | 93.95M |
| Interest Income | 9.32M | 3.71M | 420.00K | 1.94M | 6.69M | 3.62M | 2.36M | 1.81M |
| Interest Expense | 0.00 | 3.71M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.22M | 4.04M | 6.09M | 6.56M | 7.61M | 7.22M | 6.44M | 3.53M |
| EBITDA | -144.33M | -166.25M | -120.70M | -103.83M | -49.34M | 2.91M | -10.98M | -4.83M |
| EBITDA Ratio | -3,267.51% | -300.45% | -154.97% | -118.85% | -47.65% | 2.68% | -14.24% | -5.64% |
| Operating Income | -146.55M | -166.25M | -120.70M | -103.83M | -49.34M | -4.31M | -17.43M | -8.36M |
| Operating Income Ratio | -3,317.79% | -300.45% | -154.97% | -118.85% | -47.65% | -3.97% | -22.59% | -9.77% |
| Total Other Income/Expenses | 4.17M | 3.58M | 360.00K | 1.35M | 6.55M | 3.82M | 2.21M | 1.94M |
| Income Before Tax | -142.38M | -162.67M | -120.34M | -102.49M | -42.80M | -493.00K | -15.22M | -6.42M |
| Income Before Tax Ratio | -3,223.34% | -293.98% | -154.51% | -117.30% | -41.33% | -0.45% | -19.73% | -7.50% |
| Income Tax Expense | 0.00 | -3.58M | -6.51M | -8.49M | -14.30M | 3.82M | -1.06M | 500.00K |
| Net Income | -142.38M | -159.09M | -113.83M | -93.99M | -28.50M | -493.00K | -14.16M | -6.92M |
| Net Income Ratio | -3,223.34% | -287.50% | -146.15% | -107.58% | -27.52% | -0.45% | -18.35% | -8.09% |
| EPS | -1.73 | -1.99 | -1.48 | -1.37 | -0.57 | -0.01 | -0.26 | -0.13 |
| EPS Diluted | -1.73 | -1.99 | -1.48 | -1.37 | -0.57 | -0.01 | -0.26 | -0.13 |
| Weighted Avg Shares Out | 82.50M | 79.95M | 77.09M | 68.48M | 50.30M | 64.99M | 53.65M | 53.65M |
| Weighted Avg Shares Out (Dil) | 82.50M | 79.95M | 77.09M | 68.48M | 50.30M | 64.99M | 53.65M | 53.65M |
After Plunging 59.4% in 4 Weeks, Here's Why the Trend Might Reverse for NGM Biopharmaceuticals (NGM)
3 Best Penny Stocks To Buy Before November According To Insiders
After Plunging 76.6% in 4 Weeks, Here's Why the Trend Might Reverse for NGM Biopharmaceuticals (NGM)
NGM's eye drug fails in a Phase 2 clinical trial
NGM Bio to Host Conference Call to Discuss Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
NGM Biopharmaceuticals: Eye Disorder Data Due Second Half Of 2022
Executives Buy Over $15M Of 3 Stocks
NGM Bio to Participate in Upcoming Investor Conferences
5 Graham's Lost Formula Biotech Stocks to Consider for May
NGM Biopharmaceuticals: How They Changed A Dead End To A Crossroad
Source: https://incomestatements.info
Category: Stock Reports